^
Association details:
| Biomarker: | BAX overexpression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer
Published date:
04/18/2023
Excerpt:
Analysis of correlative predictors of response revealed that patients who did not overexpress βII and BAX were significantly more likely to respond to e`ribulin. PFS was significantly shorter in patients with βII and BAX overexpression, OS was significantly shorter in those with βIII and BAX overexpression....βII, βIII tubulin subtypes and BAX are predictors of response and survival.
DOI:
10.1016/j.ygyno.2023.02.016
